Updates are available Correction dated 2025-12-04
Click to view Correction: https://doi.org/10.1038/s41408-025-01431-5
-
Authors
Vetro, Calogero https://orcid.org/0000-0003-1922-5157
Garibaldi, Bruno
Grimaldi, Francesco https://orcid.org/0000-0003-4365-9406
Chiusolo, Patrizia https://orcid.org/0000-0002-1355-1587
Filì, Carla
Riva, Carola
Cardinali, Valeria
Franciosa, Marinunzia
Pilo, Federica
Palmieri, Raffaele https://orcid.org/0000-0003-2855-8121
Esposito, Lorenzo
Menotti, Diego
Perrone, Salvatore https://orcid.org/0000-0001-8196-0481
Mulè, Antonino
Alati, Caterina
Vigna, Ernesto
Dargenio, Michela
De Luca, Giulia
Sperotto, Alessandra
Tanasi, Ilaria
Papayannidis, Cristina
Molica, Matteo
Minetto, Paola
Battipaglia, Giorgia https://orcid.org/0000-0002-0695-3879
Memoli, Mara
Salutari, Prassede
Brunetti, Lorenzo
Todisco, Elisabetta
Lotesoriere, Ivana
Isidori, Alessandro
Palumbo, Giuseppe Alberto
Annunziata, Mario
Gottardi, Michele
Gentile, Massimo https://orcid.org/0000-0002-5256-0726
Martelli, Maria Paola https://orcid.org/0000-0001-9139-1729
Capelli, Debora
Martino, Massimo https://orcid.org/0000-0002-3987-419X
Rossi, Marco
Ferrara, Felicetto
Venditti, Adriano https://orcid.org/0000-0002-0245-0553
Romani, Claudio
Galimberti, Sara
Candoni, Anna
Fianchi, Luana
Pagano, Livio https://orcid.org/0000-0001-8287-928X
Marconi, Giovanni https://orcid.org/0000-0001-6309-0515
Lemoli, Roberto Massimo
Di Raimondo, Francesco
Billio, Atto
Palumbo, Fanny Erika https://orcid.org/0009-0006-4896-6666
Pane, Fabrizio
Duminuco, Andrea
Guolo, Fabio https://orcid.org/0000-0003-3166-6078
- License Information
-
More Information
Article History
Received: 29 July 2025
Revised: 17 September 2025
Accepted: 13 October 2025
First Online: 26 October 2025
Change Date: 4 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-025-01431-5
Competing interests
: D.Capelli: Honoraria: Jazz Pharmaceuticals; C.Papayannidis: Honoraria: Abbvie, Astellas, Servier, Menarini/Stemline, BMS, Pfizer, Amgen, Janssen, Incyte, Novartis, Advisory Board: Pfizer, Astellas, Janssen, GSK, Blueprint, Jazz Pharmaceuticals, Abbvie, Novartis, Delbert Laboratoires; A.Duminuco: Honoraria: Novartis, GSK, Incyte. Support for attending meetings and/or travel: AbbVie, J&J, AOP Health, Recordati Rare Diseases, BeiOne. Advisory board: Incyte, GSK; M.Rossi: Expert testimony: Abbvie; Astrazeneca. Support for attending meetings and/or travel: Abbvie; Johnson and Johnson; Amgen; Sobi. Advisory board: Sanofi; Amgen; L.Pagano Grants: Gilead, JAZZ, Menarini-Stemline, Beigene, Blueprint, Pfizer. Honoraria: Gilead, JAZZ, Menarini-Stemline, Beigene, Blueprint, Pfizer. Advisory Board: Pulmocide, Cidara; A.Venditti: Grants or contracts from any entity: Jazz Pharmaceuticals; AstraZeneca; Abbvie. Consulting fees: Jazz Pharmaceuticals; Abbvie; Servier; Istituto Gentili; BMS; Pfizer; Astellas; Otsuka; Janssen; Daiichi-Sankyo. Honoraria: Servier; Jazz Pharmaceuticals; Abbvie; Otsuka; Pfizer; Astellas; Astex; Janssen; Support for attending meetings: Servier; Janssen; Abbvie; Daiichi-Snkyo; Pfizer; Janssen; A.Candoni: honoraria: Astellas, Servier, JAZZ, Incyte, Abbvie; Otsuka; Support for attending meetings and/or travel: Abbvie, JAZZ, Gilead; L.Brunetti: Honoraria: Jazz Healthcare, Abbvie, Incite, Research support: Karyopharm Therapeutics Inc.; R.M.Lemoli: Travel grant and Speaker’s bureau for Jazz Pharma; F.Guolo: Consultancy: Astellas; JAZZ; P.Minetto: Advisory board: Menarini-Stemline; Abbvie; C.Vetro: Honoraria: JAZZ; Astellas; Advisory Board: JAZZ; Abbvie; BMS; Astellas; Incyte; Amgen; G.Marconi: Honoraria, consulting or advisor from AbbVie Inc, Astellas Pharma, AstraZeneca, Enable life science, ImmunoGen, Janssen, Menarini Group, Pfizer, Ryvu Therapeutics, SERVIER, Syros Pharmaceuticals, Takeda; Speakers’ bureau: AbbVie Inc, Astellas Pharma, AstraZeneca, ImmunoGen, Janssen, Menarini Group, Pfizer, Ryvu Therapeutics, Syros Pharmaceuticals, Takeda; Research funding from AbbVie Inc, Pfizer, Jazz Pharmaceuticals, AstraZeneca, MEI Pharma, and Daiichi Sankyo.
: The study was reviewed and approved by the Institutional review board Catania 1. Mail: celct1@policlinico.unict.it. File number 52/2021/PO. Date of approval 22.02.2021.
: All procedures were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.
